Comparative outcomes of CAR-T therapy in elderly (≥70 Years) versus younger (70 Years) patients with relapsed/refractory multiple myeloma: A real-world propensity-matched cohort study
Retrospective cohort study shows similar outcomes of CAR-T therapy in elderly and younger patients with multiple myeloma, implying safe use in older adults.
Key Points
To compare outcomes of CAR-T therapy between elderly patients (≥70 years) and younger patients (<70 years) with relapsed/refractory multiple myeloma.
Retrospective cohort analysis using TriNetX Global Network
Cohorts: elderly (≥70 years, n=466) and younger (18–69 years, n=466)
Propensity score matching based on demographics and prior treatment
Neurotoxicity events higher in elderly (HR 1.23), not statistically significant
Rates of neutropenia and anemia similar between age groups
Healthcare utilization and all-cause mortality comparable in both cohorts